Table 6.
Difference in risk of study end points among patients with AKI randomized to dual versus single renin-angiotensin system blockade
| End Point | Combination Therapy Patients with AKI | Monotherapy Patients with AKI | Hazard Ratio | 95% Confidence Interval | P Value |
|---|---|---|---|---|---|
| Death, ESRD, or decline in eGFRa | 35/118 (29.7) | 32/71 (45.1) | 0.60 | 0.37 to 0.98 | 0.04 |
| ESRD or decline in eGFRa | 23/118 (19.5) | 17/71 (23.9) | 0.77 | 0.47 to 1.24 | 0.28 |
| ESRD | 14/128 (10.9) | 9/75 (12.0) | 0.82 | 0.34 to 1.98 | 0.66 |
| Death | 15/130 (11.5) | 19/80 (23.8) | 0.45 | 0.23 to 0.88 | 0.02 |
Time-dependent analysis included AKI events occurring before reaching any component of the primary study end point adjusted for baseline eGFR and albuminuria. Data presented as number of patients with end point/number of patients at risk (%).
a
Decline in eGFR defined as an fall in eGFR of >30 ml/min per 1.73 m2 if the eGFR was ≥60 ml/min per 1.73 m2 at randomization or a decrease in eGFR of >50% if the eGFR was <60 ml/min per 1.73 m2 at randomization.